Research Analysts Issue Forecasts for Horizon Pharma PLC’s FY2018 Earnings (HZNP)

Horizon Pharma PLC (NASDAQ:HZNP) – Equities researchers at Cantor Fitzgerald cut their FY2018 EPS estimates for Horizon Pharma in a report released on Monday. Cantor Fitzgerald analyst L. Chen now anticipates that the biopharmaceutical company will post earnings of $1.21 per share for the year, down from their prior estimate of $1.39. Cantor Fitzgerald currently has a “Buy” rating and a $17.00 target price on the stock.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm had revenue of $271.60 million during the quarter, compared to analysts’ expectations of $259.74 million. During the same quarter in the previous year, the company posted $0.70 EPS. Horizon Pharma’s revenue was up 30.1% on a year-over-year basis.

Several other research analysts have also recently weighed in on the stock. ValuEngine cut shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group boosted their price objective on shares of Horizon Pharma from $16.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of Horizon Pharma in a research report on Sunday, October 22nd. Piper Jaffray Companies set a $18.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research report on Sunday, September 10th. Finally, Zacks Investment Research cut shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. Horizon Pharma currently has an average rating of “Buy” and a consensus price target of $18.75.

Horizon Pharma (NASDAQ HZNP) traded down $0.34 during mid-day trading on Thursday, reaching $14.60. 1,245,866 shares of the company traded hands, compared to its average volume of 1,632,180. The company has a quick ratio of 1.52, a current ratio of 1.64 and a debt-to-equity ratio of 1.89. Horizon Pharma has a 1 year low of $9.45 and a 1 year high of $18.31. The company has a market cap of $2,448.45, a PE ratio of -4.79, a PEG ratio of 1.27 and a beta of 1.31.

Several institutional investors have recently modified their holdings of HZNP. Bank of Montreal Can raised its position in shares of Horizon Pharma by 16.3% during the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 1,378 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Horizon Pharma by 82.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 153,668 shares of the biopharmaceutical company’s stock valued at $1,824,000 after acquiring an additional 69,626 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of Horizon Pharma by 2,170.0% during the 2nd quarter. Canada Pension Plan Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 21,700 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Horizon Pharma by 12.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 1,466 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Horizon Pharma by 3.4% during the 2nd quarter. Rhumbline Advisers now owns 210,843 shares of the biopharmaceutical company’s stock valued at $2,503,000 after acquiring an additional 6,871 shares during the last quarter. Institutional investors own 86.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Research Analysts Issue Forecasts for Horizon Pharma PLC’s FY2018 Earnings (HZNP)” was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://transcriptdaily.com/2017/12/31/research-analysts-issue-forecasts-for-horizon-pharma-plcs-fy2018-earnings-hznp.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply